BFM
APLT

Boothbay Fund Management’s Applied Therapeutics APLT Stock Holding History

Boothbay Fund Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,964
Closed -$83.6K – 1568
2023
Q4 		$83.6K Buy
+24,964
New +$62.1K ﹤0.01% 1446

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Boothbay Fund Management's APLT Position: Q1 2024 in Review

Boothbay Fund Management sold out of Applied Therapeutics (APLT) in Q1 2024, closing a stake of 24,964 shares — an estimated $83.6K sold.

Boothbay Fund Management first reported a position in APLT in Q4 2023 and held it in 1 quarter. The position peaked at $83.6K in Q4 2023. 89 funds tracked by Wall St. Rank hold APLT as of Q1 2024.

  • Boothbay Fund Management reported no remaining Applied Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 24,964 Applied Therapeutics shares in Q1 2024, an estimated $83.6K.
  • Boothbay Fund Management first reported a position in Applied Therapeutics in Q4 2023 and held it in 1 quarter.
  • Boothbay Fund Management's Applied Therapeutics position peaked at $83.6K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.